Tuesday, 19 July 2011

Twin Effects Drug, for Diabetes & Heart Disease

The new proposed drug would increase good cholesterol level as well as lower blood sugar level. Single drug would lower the risk of both most widely used diseases.

Experts on board, who are monitoring the effects of the drug in trials, are very positive about the therapeutic effect and believe that drug would be of real help.

Millions of people across the world are suffering from diabetes. Most common causes of diabetes are binge eating (or junk food), less exercise, fast life. These all factors eventually results in deadly heart disease.

Statins are most prescribed medicine to treat high level of bad cholesterol. Statin drugs are so far most effective medicine for heart disease like heart attack.

The drug of this new class is currently under trial. Working mechanism of this new drug, generic name of the drug is torcetrapib, is quite different from the other cholesterol lowering drugs. The new class is known as Cholesterylester transfer protein inhibitors (CETPs).

Torcetrapib showed promising result in trial. Level of good cholesterol found to be 65%-66% higher in patients administered with torcetrapib. Like many other treatments Torcetrapib also taken with statin drug.
Lower bad cholesterol (LDL) and higher good cholesterol (HDL) is good condition for heart. Mechanism of HDL ensures softness of blood carrying arteries.

Apart from increasing HDL, the drug also lowered sugar level by 7%. On the other side, sugar level showed no chage in patients with statin medicines only.

Trial for the similar drug was terminated as the drug found to be causing cardio problems. Later, scientists found that the negative-cardio effect was because of the drug and not class of the medicine.

Other drugs of the same class and under development are Anacetrapib and Dalcetrapib.

Currently cholesterol lowring drug generic lipitor tops the list of top selling medicine chart in USA. It would be interesting to see the market of the new drug (if it makes through).

No comments:

Post a Comment